Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06149130

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer:a Single-arm, Phase II Exploratory Clinical Study

Sponsor: Tongji Hospital

Conditions Breast Cancer

Interventions Adebrelimab dalpiciclib

Updated 4 times since 2023 Last updated: Apr 11, 2024 Started: Jan 11, 2024 Primary completion: Nov 30, 2025 Completion: Nov 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and is currently actively recruiting participants. Tongji Hospital leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2023 — May 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tongji Hospital

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China